Form 4: BeOne Medicines CEO John Oyler Reports Non-Discretionary Sale of ADSs for Tax Withholding

BeOne Medicines Ltd. CEO and Director John Oyler reported the sale of 5,127 American Depositary Shares (ADSs) on June 6, 2025, solely to cover tax withholding obligations related to the vesting of a restricted share unit award.

Summary

• John Oyler, Chief Executive Officer and Director of BeOne Medicines Ltd. (ONC), filed a Form 4 reporting transactions on June 6, 2025.
• The filing indicates the sale of a total of 5,127 American Depositary Shares (ADSs) across five separate transactions.
• The sales were executed at weighted average prices ranging from $250.8405 to $255.7376 per ADS.
• Each American Depositary Share represents 13 Ordinary Shares.
• The sales were not discretionary but were effected pursuant to a mandatory tax withholding provision in connection with the vesting of a restricted share unit (RSU) award.
• Following these transactions, John Oyler's direct beneficial ownership of American Depositary Shares is 0.
• He retains significant indirect beneficial ownership of Ordinary Shares, including 8,096,786 directly owned Ordinary Shares, 481,533 through the P&O Trust, 7,722,480 through a grantor retained annuity trust, 28,204,115 through Oyler Investment LLC, 9,545,000 through a Roth IRA PENSCO trust account, and 102,188 through The John Oyler Legacy Trust.
• Mr. Oyler disclaims beneficial ownership for shares held by the P&O Trust, the grantor retained annuity trust, Oyler Investment LLC, and The John Oyler Legacy Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale for tax withholding purposes, which does not reflect a change in management's confidence or the company's operational performance.

Positives

• The sale was a non-discretionary transaction for tax withholding, indicating it was not a sale driven by a lack of confidence in the company.
• The underlying event is the vesting of a restricted share unit award, which is a form of compensation and indicates continued service by the CEO.

Negatives

• No inherent negatives are identified as the sale was for tax withholding purposes and not a discretionary sale.

Risks

• The vesting of future restricted share units is subject to continued service, meaning Mr. Oyler must remain employed by the company for the remaining portions to vest.
• Unvested securities are subject to accelerated vesting upon a change of control or certain termination events, which could lead to further sales for tax purposes.

Future Outlook

The remaining unvested portions of the restricted share unit award will continue to vest on each anniversary of June 5, 2024, subject to John Oyler's continued service. There is also a provision for accelerated vesting upon a change of control or certain termination events.

Management Comments

• The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a non-discretionary sale for tax purposes. Such transactions are common across all industries when executives receive equity compensation that vests and triggers tax obligations. It does not provide specific insights into broader industry trends for the pharmaceutical or biotechnology sector.

Related Party Transactions

• John Oyler disclaims beneficial ownership for shares held by the P&O Trust, a grantor retained annuity trust, Oyler Investment LLC, and The John Oyler Legacy Trust, although these entities hold shares for the benefit of his family members or are related to his financial planning.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in management's outlook or company fundamentals.
• Employees: No direct impact mentioned, but the vesting of RSUs is a standard compensation practice.

Next Steps

• Future vesting of the remaining restricted share units on each anniversary of June 5, 2024, subject to continued service.

Key Dates

Keywords

SEC Form 4, Insider Transaction, BeOne Medicines Ltd., ONC, John Oyler, CEO, Director, American Depositary Shares, ADS, Restricted Share Unit, RSU, Tax Withholding, Beneficial Ownership